At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 902 enrolled
Drug / intervention
botulinum toxin neuromodulatorbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
In Brief
A Phase 3 clinical trial evaluating botulinum toxin neuromodulator for Glabellar Lines and Lateral Canthal Lines. Completed, enrolled 902 participants across 30 sites in 2 countries.
Detailed Summary
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines, Lateral Canthal Lines
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartJan 2020
Primary CompletionApr 2021
Study CompletionMay 2021
TodayJul 2026
First PostedJan 13, 2020
Enrollment StartJan 27, 2020
Primary CompletionApr 12, 2021
Study CompletionMay 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.5 years ago
Interventions
botulinum toxin neuromodulatorbiological
A dose of QM1114-DP will be injected in the GL area and in the LCL area.